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Dear Editor, 
Colonization and infection due to multidrug resistant (MDR) bacteria is nowadays an important 
issue in nosocomial and health-care associated infections, as reported by several surveillance 
systems [1-2]. The spread of MDR microorganisms has been linked to asymptomatic carriage by 
the hands of health-care workers, contamination of hospital environment, colonization of the 
bowel, use and duration of antibiotic treatments. We are currently facing new microbiological, 
infection control and clinical issues and the epidemiologic variations observed in the last years 
highlighted the need of a change from the initial proposed acronym “ESKAPE”, where MDR 
Klebsiella pneumoniae was acknowledged, to “ESCAPE” where Enterobacteriaceae and C. difficile 
were included.  
The gut microbiota regulates important physiological metabolic functions of the host and can be 
impaired during prolonged antibiotic treatments, becoming a significant reservoir of 
microorganisms with a nosocomial profile of antibiotic resistance. In C. difficile infections there is a 
clearly recognized causal role of a dysbiotic microbiota, suggesting that similar alterations may be 
favoring colonization by carbapenem-resistant K. pneumoniae (KPC-Kp) or an excessive intestinal 
growth by Candida spp., thus favoring Candida bloodstream infections. Indeed, there are reports 
of candidemia following C. difficile severe infections [3], and KPC-Kp bloodstream infections 
associated with candidemia [4]. Interestingly, in murine models of gastrointestinal candidiasis Cole 
et al. analyzed the impact of colonization of gastrointestinal mucosa, alterations of the normal 
integrity of the mucosal epithelium and impairment of mucosal immunity in the development of 
invasive candidiasis [5].  
If these considerations are correct, the gastrointestinal tube is a well recognized key player as the 
main reservoir for human disease by Candida spp. and for epidemic dissemination of MDR 
bacteria such as KPC-Kp and C. difficile. Accordingly, we propose that antimicrobial stewardship 
programs should start focusing on a “CCC” strategy, aiming at Carbapanemases-producing 
Enterobacteriacee, C. difficile and Candida spp. 
Amongst Enterobacteriacee, carbapenemases are mainly seen in KPC-producing K. pneumoniae, 
with increasing data coming not only from critically ill and surgical patients but also from internal 
medicine wards [6]. The identification of patients colonized by KPC-Kp in different settings 
deserves a dedicated intervention and a major compliance of health-care workers to simple 
standard hygiene procedures, such as hand washing [7]. The European guidelines on infection 
control issues for Gram-negative bacteria highlight the scientific evidence available on prevention 
and isolation, including C. difficile [8].    
The “CCC” acronym may help antimicrobial stewardship programs to focus on current issues and 
may guide physicians in remembering and acknowledging the importance of disturbances of the GI 
tract, including the collateral damage due to antibiotic treatment [9]. Timely identification of at-
risk patients, early treatment in symptomatic patients, antibiotic de-escalation are urgently 
needed. Save the tube! 
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